(Reuters) – The U.S. House Oversight Committee has decided to subpoena drugmaker Abbvie Inc to seek documents as part of its investigation into drug pricing practices.
“After more than 18 months, AbbVie (NYSE:) has demonstrated its unwillingness to comply voluntarily with the Committee’s investigation,” Representative Carolyn Maloney, the Chairwoman of the committee, wrote in a memo.
AbbVie did not immediately respond to Reuters request for comment.
Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.